Soft Tissue Sarcomas with Special Reference to Molecular Aberration, Chemotherapy, and Recent Advances: A Review Article

Linu Abraham Jacob¹, Sreevalli A¹, Shwetha Ninutha¹, Lokanatha Dasappa¹, Suresh Babu MC¹, Lokesh KN¹, Rudresha AH¹, Rajeev LK¹, Smita Saldanha¹

¹Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India

Abstract

Soft tissue sarcomas (STS) are a diverse group of rare solid tumors of mesenchymal cell origin with distinct clinical and pathological features. They account for less than 1% of all adult malignancies and 15% of pediatric neoplasms. They include over hundreds of different histological subtypes. Many of these subtypes can occur at any age and are not confined to a specific site. Each subtype displays variable clinical behavior. Low incidence, variable presentation, behavior, and long-term outcomes further make it challenging to treat. There are multiple ongoing trials that focus on the anatomic site and histologic subtype to tailor the treatment. Further rarity of each histotype is a major barrier to recruit patients to randomized controlled trials. A multidisciplinary approach is mandatory in all cases of soft tissue sarcomas.

The purpose of this review is to thoroughly understand the existing literature on history, incidence, epidemiology, etiology, histology, pathogenesis, diagnostic modalities, prognosis, management, and post-treatment surveillance of STS. Uterine sarcomas, gastrointestinal stromal tumors (GIST), and pediatric sarcomas are not included here. It briefly highlights various molecular aberrations, changes in staging as per the American Joint Committee on Cancer (AJCC) 8, drugs that are used off-label in specific subtypes of sarcoma along with the recent advances. The classification of STS is undergoing continuous evolution. A wide variety of subtypes can only be diagnosed accurately with sophisticated molecular diagnostic tests and with the involvement of expert geneticists and pathologists to interpret it.

There is no clarity on tailoring the treatment of STS to date. There is always a question on how best we can incorporate chemotherapy and radiotherapy along with surgery as a part of multimodality treatment. The heterogeneity of STS has hindered the development of robust, evidence-based treatment strategies, and our therapeutic approach is neither histology-specific nor widely standardized. Increased knowledge about sarcoma biology could help to discover new and more effective treatment strategies and help overcome the therapeutic challenge imposed by this deadly disease.

Keywords
- soft tissue sarcoma
- heterogenous
- mesenchyme
- molecular aberration

DOI https://doi.org/10.1055/s-0041-1740324. © 2022. Indian Society of Medical and Paediatric Oncology. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
disease. Continued collaboration among various sarcoma centers globally will be of prime importance to optimize STS management. This will allow studies to be both sufficiently large and reasonably focused to generate evidence that is clinically meaningful in specific STS patient populations.

Introduction

Soft tissue sarcomas (STS) are rare and heterogenous group of malignant tumors that originate from embryonic stem cells. Rudolf Virchow, Samuel Gross, and Samuel Wilks laid the foundation of our current understanding of soft tissue sarcomas. They represent a diverse family of malignancies comprising over hundred histological subtypes and many molecular aberrations. The delay in diagnosis and presentation with advanced disease or metastasis account for poor prognosis. The rarity of the disease along with a wide variety of subtypes has made sarcomas a challenging topic to understand.

Incidence and Epidemiology

STS comprise less than 1% of all adult malignancies and 15% of pediatric malignancies. As per National Cancer Institute Surveillance Epidemiology End Results (NCI SEER) cancer database, STS accounts for 0.7% of all new cancer cases with estimated new STS cases in 2020 being 13,130. The life time risk of developing STS is 0.4%. It is most commonly diagnosed in the age group of 65 to 74 years. It represents 0.9% of all cancer deaths.

The death rate was 1.3 per 100,000 men and women per year. As per SEER cancer database 60% of STS are localized at diagnosis, 19% spread to the regional lymph nodes, 15% have distant metastasis, and 6% are of unknown stage. The 5-year overall relative survival is 64.7%. Patients with high-grade tumors are at a significant risk for distant recurrence, and as many as 50% of these patients die of their disease. On the contrary, low-grade STS have an excellent prognosis with 5-year survival rates of 85% or more.

Histologic Subtypes

The World Health Organization (WHO) 2020 (5th edition) classifies STS based on presumptive tissue of origin, architectural pattern if of uncertain histogenesis, and genetics as shown in Table 1. As per the WHO, there are more than 100 different histologic subtypes. The most common STS in adults are liposarcoma, followed by leiomyosarcoma, undifferentiated pleomorphic sarcoma, gastrointestinal stromal tumors (GIST), and many others as shown in Fig. 1. The Network for Sarcomas (NETSARC) is a large database that enables the exploration of rare clinical and histological subtypes.

Etiology

The various etiological factors are discussed as below:

1. Genetic Predisposition

Genetic syndromes associated with STS are Li-Fraumeni syndrome (LFS), Gardner syndrome (familial adenomatous polyposis), and neurofibromatosis type 1 (NF 1). Mutations in TP53 are the most common germline mutations that predispose to sarcomas such as osteosarcoma, Ewing, and rhabdomyosarcoma. Sarcomas account for 25 to 33% of tumors seen in genetic cancer syndromes.

2. Radiation Therapy and Chemotherapy

Radiation exposure and risk of STS at 15 to 20 years is almost 0.5%. The risk is the highest in childhood cancer survivors following RT and chemotherapy with regimens containing anthracyclines and alkylating agents. The most common histopathologic type of radiation-associated sarcoma is undifferentiated pleomorphic sarcoma, previously termed malignant fibrous histiocytoma (MFH). Undifferentiated pleomorphic sarcoma (UPS) was seen in 26%, angiosarcoma in 21%, fibrosarcoma in 12%, leiomyosarcoma (LMS) in 12%, and malignant peripheral nerve sheath tumor (MPNST) in 9% of patients.

3. Chemicals

Exposure to various chemical agents such as vinyl chloride and arsenic was found to be associated with hepatic angiosarcoma. Other chemicals, exposure to which are at an increased risk of soft tissue sarcoma are thorotrast, dioxin, phenoxy herbicides, and chlorophenol.

4. Chronic Edema, Chronic Irritation Trauma

Chronic lymphedema is known to be associated with angiosarcoma. Chronic irritation secondary to foreign bodies and trauma may be responsible for abdominal desmoid.

5. Viral Infections

Viral infections such as human immunodeficiency virus (HIV), human herpesvirus-8 (HHV 8), and Epstein–Barr virus (EBV) have also been implicated in the pathogenesis of STS.

Genetics and Molecular Pathogenesis

The genetics of STS can be divided into those with simple and highly complex karyotypes. Simple karyotype includes fusion genes due to reciprocal translocations or specific point mutations/inversions. Translocation-associated sarcomas
### Table 1

**WHO histologic classification of soft tissue sarcomas**

<table>
<thead>
<tr>
<th>Group</th>
<th>Subgroup</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A) Fibroblastic/myofibroblastic tumors</strong></td>
<td>a) Benign</td>
<td>1. Angiomyofibroblastoma</td>
</tr>
<tr>
<td></td>
<td>b) Intermediate locally aggressive</td>
<td>1. Solitary fibrous tumor, benign</td>
</tr>
<tr>
<td></td>
<td>c) Intermediate rarely metastasising</td>
<td>1. DFSP - Dermatofibrosarcoma protuberans NOS</td>
</tr>
<tr>
<td></td>
<td>d) Malignant</td>
<td>1. Solitary fibrous tumor, malignant</td>
</tr>
<tr>
<td><strong>B) Fibrohistiocytic</strong></td>
<td>a) Benign</td>
<td>1. Tenosynovial giant cell tumor NOS</td>
</tr>
<tr>
<td></td>
<td>b) Intermediate (Rarely Metastasizing)</td>
<td>1. Giant cell tumor of soft part NOS</td>
</tr>
<tr>
<td></td>
<td>c) Malignant</td>
<td>1. Malignant tenosynovial giant cell tumor</td>
</tr>
<tr>
<td><strong>C) Adipocytic</strong></td>
<td>a) Benign</td>
<td>1. Lipoma NOS</td>
</tr>
<tr>
<td></td>
<td>b) Intermediate</td>
<td>1. Atypical lipomatous tumor /well differentiated liposarcoma</td>
</tr>
<tr>
<td></td>
<td>c) Malignant</td>
<td>1. Liposarcoma well differentiated NOS</td>
</tr>
<tr>
<td></td>
<td>d) Malignant</td>
<td>1. Myxoid liposarcoma</td>
</tr>
<tr>
<td></td>
<td>e) Pleomorphic</td>
<td>1. Pleomorphic liposarcoma</td>
</tr>
<tr>
<td><strong>D) Smooth muscle</strong></td>
<td>a) Benign</td>
<td>1. Leiomyoma NOS</td>
</tr>
<tr>
<td></td>
<td>b) Malignant</td>
<td>1. Leiomyosarcoma NOS</td>
</tr>
<tr>
<td><strong>E) Skeletal muscle</strong></td>
<td>a) Benign</td>
<td>1. Rhabdomyoma NOS</td>
</tr>
<tr>
<td></td>
<td>b) Malignant</td>
<td>1. Embryonal rhabdomyosarcoma NOS</td>
</tr>
<tr>
<td></td>
<td>c) Malignant</td>
<td>1. Alveolar RMS</td>
</tr>
<tr>
<td></td>
<td>d) Malignant</td>
<td>1. Myxoid rhabdomyosarcoma NOS</td>
</tr>
<tr>
<td><strong>F) Vascular</strong></td>
<td>a) Benign</td>
<td>1. Hemangioma NOS</td>
</tr>
<tr>
<td></td>
<td>b) Intermediate</td>
<td>1. Lymphangioma NOS</td>
</tr>
<tr>
<td></td>
<td>c) Intermediate rarely metastasising</td>
<td>1. Kaposis sarcoma</td>
</tr>
<tr>
<td></td>
<td>d) Malignant</td>
<td>1. Angiosarcoma</td>
</tr>
<tr>
<td><strong>G) Perivascular</strong></td>
<td>a) Benign</td>
<td>1. Neurofibroma NOS</td>
</tr>
<tr>
<td></td>
<td>b) Malignant</td>
<td>1. Chondroma NOS</td>
</tr>
<tr>
<td><strong>H) Neural</strong></td>
<td>a) Benign</td>
<td>1. Myxoma NOS</td>
</tr>
<tr>
<td></td>
<td>b) Malignant</td>
<td>1. Myxoid rhabdomyosarcoma NOS</td>
</tr>
<tr>
<td><strong>I) Extraskeletal chondro-osseous tumor</strong></td>
<td>a) Benign</td>
<td>1. Alveolar soft part sarcoma</td>
</tr>
<tr>
<td></td>
<td>b) Malignant</td>
<td>1. Synovial sarcoma (biphasic, spindle cell, poorly differentiated)</td>
</tr>
<tr>
<td></td>
<td>c) Malignant</td>
<td>1. Epithelioid sarcoma</td>
</tr>
<tr>
<td></td>
<td>d) Malignant</td>
<td>1. Epithelioid sarcoma</td>
</tr>
<tr>
<td><strong>J) Tumors of uncertain differentiation</strong></td>
<td>a) Benign</td>
<td>1. Alveolar soft part sarcoma</td>
</tr>
<tr>
<td></td>
<td>b) Malignant</td>
<td>1. Synovial sarcoma (biphasic, spindle cell, poorly differentiated)</td>
</tr>
<tr>
<td></td>
<td>c) Malignant</td>
<td>1. Desmoplastic small round cell tumor</td>
</tr>
<tr>
<td></td>
<td>d) Malignant</td>
<td>1. Epithelioid sarcoma</td>
</tr>
<tr>
<td></td>
<td>e) Malignant</td>
<td>1. Epithelioid sarcoma</td>
</tr>
<tr>
<td><strong>K) Undifferentiated/unclassified tumor</strong></td>
<td>a) Malignant</td>
<td>1. Undifferentiated pleomorphic sarcoma</td>
</tr>
<tr>
<td></td>
<td>b) Malignant</td>
<td>1. Undifferentiated round cell sarcoma</td>
</tr>
<tr>
<td></td>
<td>c) Malignant</td>
<td>1. Undifferentiated epithelioid sarcoma</td>
</tr>
<tr>
<td></td>
<td>d) Malignant</td>
<td>1. Undifferentiated sarcoma, not otherwise specified</td>
</tr>
</tbody>
</table>

**Abbreviations:** NOS, not otherwise specified; RMS, rhabdomyosarcoma.
**Fig. 1** Histologic subtypes of soft tissue sarcomas with decreasing order of frequency.3

**Table 2(a)** Sarcoma subtypes with associated translocation and genes

<table>
<thead>
<tr>
<th>Sarcoma Subtype</th>
<th>Translocation</th>
<th>Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myxoid/round cell liposarcoma</td>
<td>t(12;16)(q13;p11)</td>
<td>FUS-DDIT3 (&gt;90%)</td>
</tr>
<tr>
<td></td>
<td>t(12;22)(q13;p12)</td>
<td>EWSR1-DDIT3 (&lt;5%)</td>
</tr>
<tr>
<td>Ewing sarcoma</td>
<td>t(11;22)(q24;q12)</td>
<td>EWSR1-FLI1 (&gt;80%)</td>
</tr>
<tr>
<td></td>
<td>t(21;22)(q22;q12)</td>
<td>EWSR1-ERG (10-15%)</td>
</tr>
<tr>
<td>Desmoplastic small round cell tumor</td>
<td>t(11;22)(p13;q12)</td>
<td>EWSR1-WT1 (&gt;75%)</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
<td>t(x;18)(p11;q11) (&gt;90%)</td>
<td>SYT-SSX1 (66%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SYT-SSX2 (33%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SYT-SSX4 (&lt;1%)</td>
</tr>
<tr>
<td>Alveolar rhabdomyosarcoma</td>
<td>t(2;13)(q35;q14)</td>
<td>PAX3-FOXO1 (&lt;80%)</td>
</tr>
<tr>
<td></td>
<td>t(1;13)(p36;q14)</td>
<td>PAX7-FOXO1 (&lt;20%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PAX3-NCOA1 (&lt;1%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PAX3-NCOA2 (&lt;1%)</td>
</tr>
<tr>
<td>Alveolar soft part sarcoma</td>
<td>t(X;17)(p11;q25)</td>
<td>ASPSCR1-TFE3 (&gt;90%)</td>
</tr>
<tr>
<td>Dermatofibrosarcoma Protuberans</td>
<td>t(17;22) (&gt;75%)</td>
<td>COL1A1-PDGF</td>
</tr>
<tr>
<td></td>
<td>t(17;22)(q22;q13.1) (10%)</td>
<td></td>
</tr>
<tr>
<td>Extraskeletal myxoid chondrosarcoma</td>
<td>t(9;22)(q22;q12)</td>
<td>EWSR1-NR4A3 (75%)</td>
</tr>
<tr>
<td></td>
<td>t(9;17)(q22;q11)</td>
<td>TAF15-NR4A3 (&lt;10%)</td>
</tr>
<tr>
<td></td>
<td>t(9;15)(q22;q21)</td>
<td>TCF12-NR4A3 (&lt;10%)</td>
</tr>
<tr>
<td></td>
<td>t(3;9)(q12;q22)</td>
<td>TFG–NR4A3 (&lt;5%)</td>
</tr>
<tr>
<td>Endometrial stromal tumor</td>
<td>t(7;17)(p15;q21)</td>
<td>JAZF1-SUZ12 (30%)</td>
</tr>
<tr>
<td>Clear cell sarcoma</td>
<td>t(12;22)(q13;q12)</td>
<td>EWSR1-ATF1 (&gt;75%)</td>
</tr>
<tr>
<td></td>
<td>t(2;22)(q34;q12)</td>
<td>EWSR1-CREB1 (&lt;5%)</td>
</tr>
<tr>
<td>Infantile fibrosarcoma</td>
<td>t(12;15)(p13;q25)</td>
<td>ETV6-NTRK3 (&gt;75%)</td>
</tr>
<tr>
<td>Inflammatory myofibroblastic Tumor</td>
<td>t(1;2)(q25;p23)</td>
<td>ALK-TPM34</td>
</tr>
<tr>
<td></td>
<td>t(2;19)(p23;p13)</td>
<td>ALK-TPM</td>
</tr>
<tr>
<td></td>
<td>t(2;17)(p23;q23)</td>
<td>ALK-CLTC</td>
</tr>
<tr>
<td>Undifferentiated round cell sarcoma</td>
<td>t(X;X)(p11;p11)</td>
<td>BCOR-CCNB3</td>
</tr>
<tr>
<td></td>
<td>t(4;19)(q35;q13)</td>
<td>CIC-DUX4</td>
</tr>
<tr>
<td></td>
<td>t(10;19)(q26;q13)</td>
<td></td>
</tr>
</tbody>
</table>
account for one-third of sarcomas and is more common in young adults 30 to 40 years of age. Complex karyotype in the form of numerous genetic losses and gains is more common in the 50 to 60 years of age group. The detection of these cytogenetic abnormalities by fluorescence in situ hybridization (FISH) and reverse transcriptase polymerase chain reaction (RT-PCR) can assist in the diagnosis of specific STS as illustrated in Table 2(a), 2(b), 2(c).18

**Clinical Features**

The most common clinical presentation is a gradually enlarging painless mass. The most common site of STS is extremities of which the thighs, buttocks, and groin constitute 46%, upper extremity 13%, torso 18%, retroperitoneum 13%, and head and neck 9%. Particular histologic subtypes have proclivity to certain anatomic sites, for example liposarcomas (LPS) are more common in the thighs, desmoplastic small round cell tumors mainly involve the abdominal cavity and pelvis. The most common retroperitoneal sarcomas (RPS) are LPS and leiomyosarcomas followed by undifferentiated/unclassified STS. Well-differentiated LPS are the most common followed by dedifferentiated LPS.20

**Mode of Spread**

The most common mode of spread is hematogenous and mainly to the lungs. According to Christie-Large et al, the incidence of distant metastases at the time of diagnosis of STS was 10%, of which 83% were located in the lungs.21 Other rare sites include the liver, bone, brain, skin, and soft tissues. Extrapulmonary site metastases to retroperitoneum, spine, paraspinal tissues is seen with myxoid/round cell liposarcomas. Overall, 25% of patients will develop distant metastases after the treatment of primary disease. The chance of distant metastases is almost 40 to 50% if the tumor size is more than 5 cm, deep to fascia, and intermediate or high grade.22

Lymph node spread in STS is very rare and associated with poor prognosis. It is seen more commonly in subtypes such as rhabdomyosarcoma, synovial sarcoma, epithelioid sarcoma, clear cell sarcoma, and angiosarcoma.23

**Investigations**

Radiological diagnosis is essential to determine the extent of primary, rule out metastases, and plan surgery. Magnetic resonance imaging (MRI) is the investigation of choice for...
primary extremity lesion and also for detecting local recurrence. Computerized tomography (CT) is preferred for primary abdominal, visceral, or retroperitoneal lesion. CT chest is required as a part of staging workup to rule out pulmonary metastases. CT abdomen and pelvis need to be done in round cell/myxoid liposarcoma due to a high risk of metastasis to the abdomen and retroperitoneum, brain imaging in angiosarcoma and alveolar soft part sarcoma as high chances of brain metastases, bone scan for round cell/myxoid liposarcomas. Positron emission tomography computed tomography (PET CT) is not a part of initial staging workup of STS, including retroperitoneal sarcomas. Positron emission tomography (PET) CT is not a part of initial staging workup of STS, including retroperitoneal sarcomas, due to its restricted ability to differentiate benign from low to intermediate grade sarcomas. As per the National Comprehensive Cancer Network (NCCN), PET scan in STS may be useful for prognostication, grading, and determining the response to neoadjuvant chemotherapy.

Percutaneous core needle biopsy is indicated only if diagnosis is in doubt or if neoadjuvant therapy is planned. It is rarely performed if initial surgery is planned based on radiographic diagnosis as there is a high chance of tumor seeding. IHC, FISH, RT-PCR, and NGS are the various molecular methods to arrive at final diagnosis. Common IHC markers include NKX2.2 for Ewing sarcoma, CDK4 and MDM2 for well-differentiated/dedifferentiated LPS, TLE-1 for synovial sarcoma, H3K27me3 for MPNST, STAT6 for SFT, EBER-ISH and Pan-NTRK.

**Histologic Grading**

The grading of sarcoma includes features such as mitotic index, necrosis, cellularity, pleomorphism, and histologic subtype or differentiation. Among them, the two most important are mitotic index and the extent of necrosis. Half of retroperitoneal tumors are high grade although this varies according to histology. There are several grading systems of which the two most commonly used are the National Cancer Institute (NCI) system and the FNCLCC system—Fédération Nationale des Centres des Lutte Contre le Cancer. The prediction of distant metastasis and tumor mortality was slightly better with the FNCLCC system than the NCI system. Hence, FNCLCC is more commonly used.

**Table 3** FNCLCC histologic grading of STS

<table>
<thead>
<tr>
<th>Tumor differentiation</th>
<th>Mitotic count</th>
<th>Tumor necrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Sarcomas closely resembling normal adult mesenchymal tissue (e.g., low-grade leiomyosarcoma)</td>
<td>In most mitotically active area of the sarcoma, 10 successive HPFs are assessed using a 40x objective</td>
<td>No necrosis</td>
</tr>
<tr>
<td>2 Sarcomas of which histologic typing is certain (e.g., myxoid/round cell liposarcoma)</td>
<td>0–9 mitoses per 10 HPF</td>
<td>&lt; 50% tumor necrosis</td>
</tr>
<tr>
<td>3 Embryonal and undifferentiated sarcomas, sarcomas of doubtful type, synovial sarcoma, soft tissue osteosarcoma, Ewing sarcoma/PNET of soft tissue</td>
<td>10–19 mitoses per 10 HPF</td>
<td>≥50% tumor necrosis</td>
</tr>
<tr>
<td></td>
<td>≥20 mitoses per 10 HPF</td>
<td>Gx Grade cannot be assessed</td>
</tr>
<tr>
<td></td>
<td>Total differentiation, mitotic count and necrosis score of 2 or 3</td>
<td>G1 Total differentiation, mitotic count and necrosis score of 4 or 5</td>
</tr>
<tr>
<td></td>
<td>Total differentiation, mitotic count and necrosis score of 6, 7 or 8</td>
<td>G2 Total differentiation, mitotic count and necrosis score of 4 or 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>G3 Total differentiation, mitotic count and necrosis score of 6, 7 or 8</td>
</tr>
</tbody>
</table>

Abbreviations: HPF, high-power field; PNET, primitive neuroectodermal tumor.

Staging

The most commonly used staging system for STS is tumor, node, and metastasis (TNM) system, which was developed in collaboration with the Union for International Cancer Control (UICC) with American Joint Committee on cancer (AJCC). The AJCC TNM system uses tumor size (T), lymph node involvement (N), presence or absence of distant metastases (M) along with histologic grading (G) to determine the stage grouping. The recent AJCC 8 determines separate T staging and prognostic stage groups for STS of extremity/trunk and retroperitoneum unlike AJCC 7 as given below in **Table 4(a)**. It also describes a separate T staging for STS of the abdomen and thorax but no separate N and M and prognostic stage groupings (**Table 4(b)**). TNM staging for retroperitoneal sarcomas is same as for the trunk and extremities, except that any T, N1 M0 of any grade is stage IIIIB and not stage IV.
Prognostic Factors

The most important prognostic factors include histologic grading, tumor size, and pathologic stage at diagnosis. Others include histologic subtype, anatomic site, depth, patient age, positive margin, recurrent disease at presentation. Patients with extremity and superficial trunk lesions have better prognosis compared to retroperitoneal and visceral sarcomas.

Grade is an independent predictor of early distant metastases and death. The initial tumor size determines the chances of local recurrence and distant metastases. In a review by Suit et al from Massachusetts General Hospital (MGH), the frequency of distant metastasis increased with an increase in the tumor size, accounting for 38% of tumors 5–10 cm, 49% of tumors 10.1–15 cm, 58% for tumors 15.1–20 cm, and 83% for tumors > 20 cm. Bone and neurovascular invasion are associated with bad prognosis.

Grade, completeness of resection, presence or absence of metastatic disease are independent prognostic factors for disease-specific survival in case of retroperitoneal sarcomas. Patients with MPNST, LMS, high-grade liposarcoma had worse survival compared to solitary fibrous tumor (SFT), low-grade liposarcoma. A nomogram developed by the Memorial Sloan-Kettering Cancer Centre (MSKCC) aids in predicting survival and treatment decision-making for individual patients. It includes patients’ age, tumor size, FNCLCC grade, histologic subtype, multifocality, and the extent of resection.

Treatment

Soft Tissue Sarcoma of Extremities

The main aim of treating STS of extremities is to improve survival, prevent local and distant recurrences, improve limb function, and minimize morbidity and mortality. The only curative approach is surgical resection. Radiotherapy is indicated for more than 5 cm tumor to improve local control. The role of chemotherapy in adjuvant and neoadjuvant setting is still controversial.
**Adjuvant Chemotherapy**

Despite 20 randomized controlled trials (RCTs) and two meta-analyses, data on adjuvant chemotherapy are still irreconcilable. As per NCCN and ESMO, adjuvant chemotherapy is an option for high-risk patients—deep-seated STS, high-grade, large primary ≥ 5 cm, locally recurrent extremity sarcoma. Present approach is to individualize treatment based on performance status (PS), age, comorbidity, site of the disease, histology such as synovial sarcoma, leiomyosarcoma, and myxoid round cell liposarcoma, which are chemosensitive.

Sarcoma meta-analysis collaboration (SMAC) in 1997 included 14 RCTs of doxorubicin-based adjuvant chemotherapy (less than 5% received ifosfamide-containing regimen) after local treatment of 1,568 adults with localized resectable STS. The median follow-up was 9.4 years. It was observed that doxorubicin-based adjuvant chemotherapy significantly improved the time to local recurrence with hazard ratio (HR) of 0.73 (95% confidence interval [CI]: 0.56–0.94) and distant recurrence with HR of 0.70 (95%CI: 0.57–0.85), and overall recurrence-free survival (RFS) in adults with HR of 0.75 (95%CI: 0.64–0.87) and an absolute 6 to 10% improvement in RFS at 10 years. There was a trend toward OS although not statistically significant. There was no difference in the outcome in relation to various parameters such as age, sex, stage, site, grade, histology, extent of resection, tumor size, or exposure to radiotherapy. However, on subset analysis those with extremity and truncal sarcomas had significant OS benefit. There was almost 7% absolute benefit in OS at 10 years in those receiving doxorubicin-based regimens, which was statistically significant.13,34

However, the main drawback of this meta-analysis was it included only one negative trial of the two European organizations for research and treatment of cancer (EORTC) negative trials.

Petroi et al in an Italian trial included 88 patients with high-risk extremity sarcoma were randomized to surgery with or without RT and surgery with or without RT with chemotherapy (epirubicin or IE regimen). The 5-year disease-free survival (DFS) and OS were higher in chemotherapy arm, which was statistically significant accounting for 69% versus 44% and 72% versus 47%, respectively.35 This study highlights the advantage of epirubicin-based adjuvant chemotherapy in high-risk STS.

EORTC and an Austrian trial could not demonstrate the survival benefit from adjuvant doxorubicin- and ifosfamide-containing regimens.36,37 EORTC included 351 patients with completely resected STS, of which 67% were extremity tumors, 60% were high grade, and 40% were ≥10 cm in size. There was no difference in DFS and OS in chemotherapy (five cycles of ifosfamide 5 gm/m² cycle and Adriamycin 75 mg/m²-IA) and observation arm.36 The limitations of these studies were small number of patients, admittance of non-extremity, small and low/intermediate-grade primaries, and the use of relatively low ifosfamide dose.

Pervaiz et al in 2008 demonstrated the benefit of chemotherapy in an updated systematic meta-analysis (SMAC) of 18 RCTs. It included negative trials such as Austrian and two Italian trials but not the EORTC trial. A total of 1,953 patients with localized surgically amenable STS were included between 1973 and 2002 (five trials used IA regimen, while others used either doxorubicin alone or a combination regimen). The odds ratio (OR) for local and distant recurrence favored chemotherapy similar to the SMAC meta-analysis. When compared to the SMAC meta-analysis, doxorubicin and ifosfamide were associated with statistically significant OS benefit (HR for death: 0.56, 95% CI: 0.36–0.85) with an absolute risk reduction accounting to 11% (30 vs. 41% risk of death). However, the benefit could not be shown for doxorubicin alone. Thus, ifosfamide is of utmost importance in adjuvant setting of sarcomas.

**Role of tumor histology, grade, and size in adjuvant therapy**

There are no prospective trials to prove the same. Three retrospective studies have showed benefit of adjuvant chemotherapy in chemosensitive subtypes such as myxoid round cell liposarcoma and synovial sarcoma. In a single center Italian trial of 251 patients with localized synovial sarcoma, 61 patients who had undergone macroscopically complete resection, received adjuvant chemotherapy. The 5-year metastasis-free survival (MFS) in chemotherapy arm was 60% as against 48% in surgery only arm. The benefit was more for those older than 17 years and ≥5 cm tumor size (MFS: 47 vs. 27%, respectively).38 However, as per both MSKCC and MD Anderson retrospective data between 1984 and 1999, patients undergoing adjuvant chemotherapy for high-grade, ≥5 cm extremity STS did not show any benefit.39

The optimal regimen is unspecified— the AIM regimen consisting of adriamycin 75 mg/m², ifosfamide 9–10 gm/m² D1-D3 with mesna every three weekly for a total of six cycles is used commonly.

**Neoadjuvant Chemotherapy**

The role of neoadjuvant therapy is in large, recurrent, and high-grade tumors where limb salvage is an issue. The correct sequencing of chemotherapy (CT), RT, and surgery is unknown. The main purpose of neoadjuvant therapy is the treatment of micro metastases, need for less radical surgery, and more effectiveness of preop RT or chemotherapy. There are no randomized phase III trials to support neoadjuvant chemotherapy. A randomized phase II EORTC study of 150 patients randomizing them to three cycles of neoadjuvant ifosfamide and Adriamycin versus surgery alone was negative.

**Role of histology in neoadjuvant therapy**

In a phase III multicentric randomized trial, as compared to histology-based treatment with high-dose ifosfamide alone for synovial sarcoma, gemcitabine plus dacarbazine for LMS, gemcitabine plus docetaxel for undifferentiated pleomorphic sarcoma, trabectedin for high-grade myxoid liposarcoma, etoposide plus ifosfamide for MPNST, anthral-cycline-based regimen (IE regimen) showed DFS benefit among all histologies including LMS and MPNST. Data are still not convincing as to how epirubicin influenced the trial
results as doxorubicin is more commonly used in all other trials.

- **Retropertitoneal Sarcomas**
  The only curative treatment for RPS has been surgery. The ability to achieve R0/R1 resection at the time of initial presentation is the most important prognostic factor for survival. Debulking surgery (R2 resection) should be preferred only in large unresectable well-differentiated retropertitoneal liposarcomas, which aids in symptom improvement and prolongs survival.

  Intra-op radiotherapy (IORT) of 10 to 15 Gy can be administered to the areas of residual microscopic or gross disease as it improves local control, RFS, and OS. However, no RCTs are available to support the same. Reresection is advised for gross residual disease (R2 resection), if technically feasible.

**Adjuvant Therapy**
Evidence for adjuvant therapy for RPS, may it be RT and/or chemotherapy, is lacking. Adjuvant RT is indicated for intermediate- to high-grade tumors and incompletely resected tumors at high risk for recurrence. Survival benefit has been demonstrated in retrospective and case-control studies. Postoperative RT enhances local tumor control and has shown a trend toward long-term RFS. However, the management of radiation-associated morbidity is challenging. Hence, safe delivery of RT is feasible preoperatively than postop. Anthracycline/ifosfamide-containing regimen significantly improved the survival as per an updated meta-analysis but it did not include two negative trials.

**Neoadjuvant Therapy**
Data on neoadjuvant chemotherapy for RPS are very limited. As per the ESMO guidelines tailoring treatment is based on histology and grade. In case of large well-differentiated liposarcoma (WD LPS), intermediate-and high-grade tumors that are not chemosensitive or patient not suitable for chemotherapy neoadjuvant RT, followed by a surgery is preferred. Pre-op RT permits safe delivery of higher doses than in post-op setting and is biologically more effective; however, no RCTs are available as yet to support the same in RPS. Results of STRASS I, a randomized EORTC phase III trial is awaited. Intensity modulated radiotherapy (IMRT) has the ability to improve the therapeutic index; however, longer follow-up is needed.

There are no randomized control trials on concurrent chemotherapy, RT permits safe delivery of higher doses than in post-op setting and is biologically more effective; however, no RCTs are available as yet to support the same. Reresection is advised for gross residual disease (R2 resection), if technically feasible.

- **Metastatic STS**
  Once distant metastases develop, the median survival is 12 to 19 months. Surgical resection of isolated pulmonary metastatic disease results in long-term RFS with 5-year survival of 25 to 40%. In patients with unresectable disease, about 20 to 25% are still alive at 2 to 3 years. However, the survival is dependent on disease biology, histology, and treatment received.

  For asymptomatic, low-grade, unresectable tumors such as low-grade intra-abdominal LMS, intra-abdominal WDLPS, follow-up may be reasonable. Patients with good performance status (PS), minimal comorbidity with anthracycline sensitive high-grade histologies (→ Table 5), chemotherapy with doxorubicin with or without ifosfamide is preferable.

Combination chemotherapy with doxorubicin ifosfamide instead of single agent doxorubicin is chosen for symptomatic patients who require rapid tumor response. Gemcitabine-based chemotherapy is preferred for those with contraindication to anthracyclines such as cardiac failure, who have received doxorubicin cumulative dose of ≥ 375 mg/m². Paclitaxel is an advisable alternative to anthracyclines for initial treatment of angiosarcoma. Various combination regimens available are doxorubicin plus ifosfamide with mesna (AIM), or AIM with dacarbazine (MAID), gemcitabine plus either docetaxel, vinorelbine, or dacarbazine, doxorubicin plus dacarbazine. Combination regimens are associated with higher response rates (18–46%) when compared to single-agent doxorubicin (12–18%).

### Table 5 Tumor sensitivity to anthracycline

<table>
<thead>
<tr>
<th>Anthracycline-sensitive histology</th>
<th>Anthracycline-resistant histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leiomyosarcoma</td>
<td>Alveolar soft part sarcoma</td>
</tr>
<tr>
<td>Myxoid/round cell liposarcoma</td>
<td>Extraskeletal myxoid chondrosarcoma</td>
</tr>
<tr>
<td>Dedifferentiated and pleomorphic liposarcoma</td>
<td>Solitary fibrous tumor Hemangiopericytoma</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
<td>PEComas: angiomylipoma/lymphangioleiomyomatosis</td>
</tr>
<tr>
<td>Epithelioid sarcoma (ES)</td>
<td>Tenosynovial giant cell tumor (TGCT)</td>
</tr>
<tr>
<td>Angiosarcoma</td>
<td>Clear cell sarcoma</td>
</tr>
<tr>
<td>Undifferentiated pleomorphic sarcoma</td>
<td>Dermatofibrosarcoma protruberans (DFSP)</td>
</tr>
<tr>
<td>Malignant pleomorphic sarcoma</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: DFSP, dermatofibrosarcoma protruberans; ES, epithelioid sarcoma; PEComas, perivascular epithelioid cell tumor; TGCT, tenosynovial giant cell tumor.
Patients with poor PS, multiple comorbidities single-agent gemcitabine, pegylated liposomal doxorubicin are the options. Single-agent doxorubicin, epirubicin, and ifosfamide provide response rates (RR) of more than 20% in metastatic STS.\(^1\)\(^7\) Other single agents such as vinorelbine, dacarbazine, temozolomide particularly for leiomyosarcomas have a RR less than 20%.\(^5\)\(^4\)

For patients with metastatic or advanced STS with anthracycline-resistant histologies, the following are the options:

- Pazopanib or sunitinib can be used for alveolar soft part sarcoma or extraskelatal myxoid chondrosarcoma with symptomatic or progressive disease. Phase II elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ), a trial showed that pazopanib was noninferior to doxorubicin in terms of PFS (median PFS 4.4 vs. 5.3 months, HR: 1.00, 95%CI: 0.65–1.53) with similar OS.\(^5\)\(^5\)

- Dacarbazine with or without doxorubicin, temozolomide plus bevacizumab, pazopanib or sunitinib are the options for SFT/hemangiopericytoma.\(^5\)\(^5\)

- Imatinib is an alternative for locally advanced, metastatic, or recurrent dermatofibrosarcoma protuberans (DFSP) as per a systematic review (complete response [CR] in 5.2% and partial response [PR] in 55.2%).\(^5\)\(^6\)

- Sirolimus can be chosen for symptomatic progressive, recurrent perivascular epithelioid cell differentiation PEComas including angiomyolipoma/lymphangioleiomyomatosis.\(^5\)\(^7\)

- Pexidartinib colony-stimulating factor 1 receptor (CSF1R) inhibitor is an option for unresectable, recurrent, or relapsed tenosynovial giant cell tumor (TGCT) based on positive results from phase III ENLIVEN trial.\(^5\)\(^8\)

- Cediranib has substantial single-agent activity in metastatic alveolar soft part sarcoma (ASPS) with an ORR of 35% and a disease control rate of 84% at 24 weeks.\(^5\)\(^9\)

### Options for Second Line

For patients with good PS who progress on doxorubicin-based first line, later therapies are based on histology, which may include

- Gemcitabine docetaxel combination regimen for LMS, MFH.\(^6\)\(^0\) PLD, gemcitabine alone or combination regimens, ifosfamide alone or with doxorubicin are the other chemotherapy options.\(^5\)\(^1\)

- Trabectedine is an option for advanced LMS, myxoid/round cell liposarcoma and translocation-related sarcomas based on phase III, T-SAR trial with OS and PFS benefit in those previously treated with anthracycline-based chemotherapy when compared to dacarbazine.\(^6\)\(^2\) Three-weekly regimen was superior to weekly dosing.

- Eribulin can be preferred over trabectedine for pleomorphic and dedifferentiated liposarcomas due to better OS and PFS and similar PFS and OS in LMS when compared to dacarbazine.\(^6\)\(^3\)

- Pazopanib is an alternative for non-adipocytic advanced sarcomas—mainly LMS, synovial sarcoma, angiosarcoma, SFT. Phase III PALETTE trial showed a significant PFS benefit (median PFS 4.6 vs. 1.6 m) when compared to placebo.\(^6\)\(^4\)

- Among patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib significantly prolonged PFS and induced durable responses in a phase III trial.\(^6\)\(^5\)

- Larotrectinib or entrectinib could be an option for tumors with gene fusions involving one of neurotrophic tyrosine receptor kinase (NTRK) genes. ALKA, STARTRK-1, and STARTRK-2 trials demonstrated an ORR of 46% with entrectinib and 75% with larotrectinib.\(^6\)\(^6\),\(^6\)\(^7\)

- Pembrolizumab is an alternative for microsatellite instability (MSI) high/mismatch repair-deficient STS.\(^6\)\(^8\)

### Recent Advances

- Doxorubicin with olaratumab in phase III ANNOUNCE trial showed an inferior PFS and hence olaratumab has been withdrawn from the market.\(^6\)\(^8\)

- In a phase III trial evofosfamide in combination with doxorubicin compared to doxorubicin alone in previously untreated patients with locally advanced, unresectable, or metastatic STS showed no significant difference in median OS and PFS.\(^6\)\(^9\)

- Aldoxorubicin, a tumor-targeted doxorubicin conjugate, in a phase III study, showed significant PFS (5.3 vs. 2.9 months) and disease control rate (41.7 vs. 27%) in a subcohort of L-sarcomas.\(^7\)\(^0\)

- Tazemetostat, first and only Enhancer of zeste homolog (EZH2) inhibitor—a epigenetic regulator—was approved by the Food and Drug Administration (FDA) for advanced, recurrent metastatic epithelioid sarcoma (ES) not amenable for resection on Jan 23, 2020, based on a phase II trial.\(^6\)\(^9\)

- Pazopanib can be used as an initial therapy in anthracycline-sensitive advanced STS histologies for elderly who may not tolerate doxorubicin (October 2020, phase II study).\(^5\)\(^5\)

- Crizotinib in phase I/II trial, demonstrated CR and PR in 36% and 50% of inflammatory myofibroblastic tumor (IMT) with ALK translocation. More recently, ceritinib was thought to improve disease-free interval in those with acquired resistance to crizotinib.\(^7\)\(^1\)

- Anlotinib in a phase II study showed a statistically significant PFS benefit when compared to placebo in metastatic STS who had failed standard chemotherapy (China FDA in 2019).\(^7\)\(^2\)

- Maintenance ridaforolimus for advanced STS in a phase III study showed 28% reduction in PFS after four cycles of chemotherapy (SUCCEED).\(^7\)\(^0\)

- Palbociclib and abemaciclib in several phase I/II trials was associated with a favorable PFS of 66% in patients with cyclin-dependent kinase 4 (CDK4)-amplified WDLS/DDLS who had progressive disease despite systemic therapy.\(^7\)\(^3\)
Selinexor, an oral selective inhibitor of nuclear exportin protein in phase II/III trial (SEAL) for patients with DDLS showed improved PFS. Currently, recruitment of patients for phase III portion is ongoing.  

Follow-Up

As per NCCN and ESMO, follow-up is recommended every three to six monthly with history and physical examination for 2 to 3 years, then every 6 months for next 2 years, and then annually for 10 years. Periodic imaging of the primary site and CT chest for histologies with high chance of pulmonary metastases is recommended on follow-up.  

Conclusion

Heterogeneity of STS makes it a challenging rare malignancy to treat. The disease has got diverse outcomes determined by numerous factors. Prognostic factors and molecular aberrations should be taken into account while tailoring the treatment plan. A multidisciplinary approach is warranted. Many randomized prospective trials including patients with a single histological subtype of STS are needed due to heterogeneity across the histological subtypes and also in terms of chemosensitivity to formulate uniform guidelines for management of the same.

Authors’ Contributions

LAJ, SA, SN, and LD contributed to the conception of the study. SA, LAJ, LD, and SS were responsible for the acquisition. SA, LAJ, SBMC, LKN, AHR, and LKR drafted the manuscript. LD, LAJ, and LKR substantively revised it. All authors have read and approved the manuscript.

Funding

None.

Conflict of Interest

None declared.

Acknowledgments

We would like to thank the residents and faculty of the Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore.

References

1 Gross SD, (Samuel D), A System of Surgery: Pathological, Diagnostic, Therapeutic, and Operative. Philadelphia: H.C. Lea; 1866
2 VIRCHOW. Rudolf (1821–1902). Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. Berlin: August Hirschwald; 1858
3 Fletcher CDM B, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013
Soft Tissue Sarcoma: A Review

Jacob et al.


56 Navarrete-Dechent C, Mori S, Barker CA, Dickson MA, Nehal KS. Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review. JAMA Dermatol 2019;155(03):361–369


75 Patel SR, Zagars GK, Pisters PWT. The follow-up of adult soft-tissue sarcomas. Semin Oncol 2003;30(03):413–416